Glaukos (GKOS)

Executive Summary

Glaukos Corporation is a leading ophthalmic medical technology and pharmaceutical company, renowned for its pioneering micro-invasive glaucoma surgery (MIGS) devices, particularly the iStent family, with over 3 million implants. The company is transitioning toward pharmaceutical drug delivery with its iDose TR (travoprost intraocular implant), approved in late 2024, offering a dropless, sustained-release option for open-angle glaucoma. Glaukos's pipeline includes a Phase 3 travoprost intraocular implant for a broader indication and GLK-321, a Phase 2 candidate for Demodex blepharitis. With a robust commercial base and innovative pipeline addressing unmet needs in glaucoma and corneal diseases, Glaukos is well-positioned for sustained growth. The company's strong clinical evidence and expanding portfolio support its leadership in the ophthalmic space.

Upcoming Catalysts (preview)

• Q3 2026iDose TR label expansion or real-world data update75% success
• Q4 2026GLK-321 Phase 2 top-line results for Demodex blepharitis60% success
• Q2 2027Travoprost intraocular implant Phase 3 enrollment completion80% success